177 related articles for article (PubMed ID: 37916262)
1. Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
Caleffi-Marchesini ER; Herling AA; Macente J; Bonan RH; de Freitas Lima P; Moreno R; Alexandre V; Charbe NB; Borghi-Pangoni FB; Cristofoletti R; Diniz A
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):208-221. PubMed ID: 37916262
[TBL] [Abstract][Full Text] [Related]
2. Exploring in vitro solubility of lamotrigine in physiologically mimetic conditions to prospect the in vivo dissolution in pediatric population.
Caleffi-Marchesini ER; Borghi-Pangoni FB; Macente J; Chiamulera-Mantovani P; Mazucheli J; Cristofoletti R; Diniz A
Biopharm Drug Dispos; 2023 Apr; 44(2):147-156. PubMed ID: 36951570
[TBL] [Abstract][Full Text] [Related]
3. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling.
Guimarães M; Somville P; Vertzoni M; Fotaki N
J Pharm Sci; 2021 Dec; 110(12):3874-3888. PubMed ID: 34530004
[TBL] [Abstract][Full Text] [Related]
5. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
Kambayashi A; Dressman JB
J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
[TBL] [Abstract][Full Text] [Related]
6. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
Kollipara S; Bhattiprolu AK; Boddu R; Ahmed T; Chachad S
AAPS PharmSciTech; 2023 Feb; 24(2):59. PubMed ID: 36759492
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
[TBL] [Abstract][Full Text] [Related]
8. Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
Kourentas A; Gajewska M; Lin W; Dhareshwar SS; Steib-Lauer C; Kulkarni S; Hirsch S; Heimbach T; Mueller-Zsigmondy M
AAPS J; 2023 Feb; 25(1):25. PubMed ID: 36788163
[TBL] [Abstract][Full Text] [Related]
9. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
Guimarães M; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
[TBL] [Abstract][Full Text] [Related]
10. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
Jereb R; Kristl A; Mitra A
Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
Loisios-Konstantinidis I; Dressman J
Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
[TBL] [Abstract][Full Text] [Related]
12. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
[TBL] [Abstract][Full Text] [Related]
13. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
14. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
Wu D; Li M
Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
Charoo NA; Cristofoletti R; Dressman JB
J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
Eckernäs E; Tannergren C
Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Impact of Physiological Properties of the Gastrointestinal Tract On Drug In Vivo Performance Using Physiologically Based Biopharmaceutics Modeling and Virtual Clinical Trials.
Jereb R; Opara J; Bajc A; Petek B
J Pharm Sci; 2021 Aug; 110(8):3069-3081. PubMed ID: 33878322
[TBL] [Abstract][Full Text] [Related]
18. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
19. A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.
Bermejo M; Hens B; Dickens J; Mudie D; Paixão P; Tsume Y; Shedden K; Amidon GL
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963448
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
